About the Problem Statement:

Teijin Pharma Limited (Teijin) is looking for solutions to treat neurological diseases in the Japanese population.

Hardware MedTech startups for neuromodulation and software startups experience in healthcare for a mobile app would be relevant.

Objectives:

To save and reduce patients with neurological diseases relating to the central nervous system, including psychiatric and neurodegenerative diseases. Solution examples include user-friendly therapeutic modalities like non-invasive neuromodulation and/or digital therapeutics at home.

Working Model:

Teijin is open to discussing the collaboration model with startups but typically takes responsibility for technology development for the Japanese market, conducting clinical studies, regulatory / reimbursement tasks and finally commercialisation in Japan.

To achieve the goal, Teijin will invest with dilutive (equity) and/or non-dilutive funding in the partner(s).